Shionogi & Co. Ltd.

SGIOY | OTC

Price Alert Chart Builder DCF Calculator

$9.40

-$0.03 (-0.32%)

Sep 22, 2026, 3:55 PM ET · Market open

Overview Rating Statistics Financials Earnings Ownership Dividends Profile

-0.32%

(1D)

Rating

Updated: Sep 17, 2026

48.5

Fundamentals Average

Market Sentiment Neutral

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $16B

1D Range

9.32 9.50

52W Range

7.65 12

Valuation (TTM)

PE 9.24

PB 1.48

EV/EBITDA 11.45

Valuation (NTM)

Forward PE 11.31

Forward PEG 3.62

Price Target N/A

Cash Flow

FCF Yield 8.1%

SBC Adj. FCF Yield 8.1%

SBC Impact N/A

Margins

Gross Margin 78.3%

Operating Margin 29.2%

FCF Margin 35.8%

Growth (CAGR)

Revenue 3Y | 5Y 7.0% | 14.0%

Dil EPS 3Y | 5Y 13.0% | 18.7%

FCF 3Y | 5Y 11.7% | 19.5%

Returns

ROA 9.9%

ROE 16.5%

ROIC 6.5%

Financial Health

Net Debt

¥364.48B ($2.24B)

Current Ratio 1.14

Interest Coverage 14.22

Dividends

Div Yield 2.13%

Payout Ratio 0.1%

FCF Payout Ratio 29.3%

All Key Statistics

Loading financial charts...

Profile

A detailed description of the company is not yet available.

Sector n/a

Industry n/a

Employees n/a

IPO Date n/a

Website n/a

Fiscal Year n/a

Full Company Profile

Latest News

15 days ago · businesswire.com

Shionogi to Showcase Advancements Across its Infectious Disease Portfolio at IDWeek 2026

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.), will present findings from across its broad anti-infective portfolio at IDWeek 2026 (October 21-24, 2026), in Washington, D.C. Data highlights at IDWeek 2026 include an oral presentation featuring a subpopulation analysis from the global Phase 3 SCORPIO-PEP trial, a rapid-fire session focused on ventilator-ass.

27 days ago · businesswire.com

Shionogi Announces U.S. Government Procurement of Fetroja® (cefiderocol) Through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that the Biomedical Advanced Research and Development Authority (BARDA) has exercised a $36.9 million procurement option, under Project BioShield funding, from its April 2026 contract with Shionogi Inc., a New Jersey-based subsidiary of Shionogi, to procure Fetroja® (cefiderocol) as a critical countermeasure against difficult-to-trea.

2 months ago · zacks.com

Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Beats Q1 Earnings Estimates

Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.18 per share.

2 months ago · zacks.com

Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth

Shionogi & Co. (SGIOY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings

Next Earnings

Oct 26, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞